Research finding challenge the widely-held notion that cosmetic contact lenses are the safest technique for changing eye colour

A pair of studies, conducted in Taiwan and China, indicate that red light therapy could serve as an effective and safe alternative to atropine

Biomarkers and fine-tuned staging are key to progress in improving retinal care, according to Fanka Gilevska, MD, PhD

Patient response focused on perceived vision-related quality of life outcomes, investigators said

Dr Miere presented the ACTOR study, illuminating vascular remodeling in patients with neovascular AMD, and the HERMES study, investigating perfusion changes in central retinal vein occlusion

María Berrocal, MD, spoke about the Vit-Buckle Society (VBS), which has become a regular feature at the European Society of Retina Specialists annual meeting

The procurement follows an 18-month pilot at a high-volume surgery in Dundee, Scotland

Prof Romano stressed the importance of matching procedure to patient, not just mastering technical vitrectomy skills

An expert discusses evolving best practices in the diagnosis and management of Demodex blepharitis, highlighting collarettes as pathognomonic and sufficient for diagnosis, the importance of targeting high-risk patient groups for treatment, and the promise of a new pharmacologic therapy that shifts care toward a more effective, flexible, and patient-centered approach.

EyeArt uses artificial intelligence for autonomous detection of vision-threatening diabetic retinopathy

The newly-approved technology delivers low-dose microcurrents through closed eyelids to stimulate retinal cells

Today, over 150 practitioners from 20 countries in Australia, Asia and Europe enter their patient data into the Fight Retinal Blindness! Registry

The current staging system fails to fully capture the neurovascular unit's status, said Stela Vujosevic, Md, PhD, FEBO

At the EURETINA congress, Prof Boon discussed controversies in treatment, some driven by critical prospective studies

Alteogen received a positive CHMP opinion for EYLUXVI in July 2025